Long-term Change in the Risk of Skin Cancer After Organ Transplantation

Abstract

The high risk of skin cancer after organ transplantation is a major clinical challenge and well documented, but reports on temporal trends in the risk of posttransplant cutaneous squamous cell carcinoma (SCC) are few and appear contradictory. OBJECTIVE To study temporal trends for the risk of skin cancer, particularly SCC, after organ transplantation. DESIGN, SETTING, AND PARTICIPANTS Population-based, nationwide, prospective cohort study of 8026 patients receiving a kidney, heart, lung, or liver transplant in Norway from 1968 through 2012 using patient data linked to a national cancer registry. The study was conducted in a large organ transplantation center that serves the entire Norwegian population of approximately 5.2 million. EXPOSURES Receiving a solid organ transplant owing to late-stage organ failure, followed by long-term immunosuppressive treatment according to graft-specific treatment protocols. MAIN OUTCOMES AND MEASURES Occurrence of first posttransplant SCC, melanoma, or Kaposi sarcoma of the skin. Risk of skin cancer was analyzed using standardized incidence ratios (SIRs) and, for SCC, multivariable Poisson regression analysis of SIR ratios, adjusting for 5-year time period of transplantation, different follow-up time, age, sex, and type of organ. RESULTS The study cohort included 8026 organ transplant recipients, 5224 men (65.1%), with a mean age at transplantation of 48.5 years. Median follow-up time was 6.7 years per recipient; total follow-up time, 69 590 person-years. The overall SIRs for SCC, melanoma, and Kaposi sarcoma were 51.9 (95% CI, 48.4-55.5), 2.4 (95% CI, 1.9-3.0), and 54.9 (95% CI, 27.4-98.2), respectively. In those who underwent transplantation in the 1983-1987 period, the unadjusted SIR for SCC was 102.7 (95%, 85.8-122.1), declining to 21.6 (95% CI, 16.8-27.0) in those who underwent transplantation in the 2003-2007 period. Adjusting for different follow-up times and background population risks, as well as age, graft organ, and sex, a decline in the SIR for SCC was found, with SIR peaking in patients who underwent transplantation in the 1983-1987 period and later declining to less than half in patients who

Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study

“…The SUNTRAC tool was built from risk factors identified from a large, representative heterogeneous population of US‐based transplant recipients, and aims to optimize screening in a resource‐limited healthcare system. Another strength of this screening tool is the inclusion of patients transplanted as late as 2003 and 2008, allowing for satisfactory follow‐up time, but avoiding a possible bias from the declining risk of post‐transplant skin cancer since the mid‐1980s .…”

Kaposi sarcoma in Southern Finland (2006–2018)

“…The prevalence of KS after heart transplant varies according to geographic areas from 0.4 to 11% . According to a recent Norwegian study, the risk of KS in an organ transplant patient is multiplied by 55 . Most cases of posttransplant KS develop as a result of HHV8 reactivation.…”

Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis

“…2,3 The most common NMSC among this population is cutaneous squamous cell carcinoma (SCC), followed by basal cell carcinoma (BCC), 1 which together account for 95% of skin cancers in organ transplant recipients. 4 Individuals after solid organ transplantation had a higher risk for NMSC compared to the general population, 5,6 and this risk increased with time after transplantation. 7 Moreover, NMSC appears to be more aggressive among solid organ transplant recipients than in the general populations, which increases mortality among solid organ recipients.…”